Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68 gallium labelled FF58 - Advanced Accelerator Applications

Next Previous
Drug Profile

68 gallium labelled FF58 - Advanced Accelerator Applications

Alternative Names: 68Ga-FF-58

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advanced Accelerator Applications
  • Developer Advanced Accelerator Applications; Novartis
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Brain cancer; Glioblastoma

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Brain-cancer(Diagnosis) in France (IV, Injection)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Glioblastoma(Diagnosis) in France (IV, Injection)
  • 27 Dec 2024 Novartis Pharmaceuticals terminates a phase I trial in Solid tumours (Diagnosis, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Prevention of relapse, Recurrent) in Spain, Netherlands, Italy, Israel and the US (Parenteral) (NCT05977322) (EUCT-2020-502367-37-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top